Tianjin TEDA Biomedical Engineering Company Limited
Simbolis: 8189.HK
HKSE
0.068
HKDRinkos kaina šiandien
-5.7818
P/E santykis
0.0135
PEG koeficientas
118.41M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Tianjin TEDA Biomedical Engineering Company Limited (8189-HK) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 5.9 | 9.5 | 29.8 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 2.7 | 3.3 | |||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 8.8 | 31.9 | 32.1 | |||||||||||||||||||
balance-sheet.row.inventory | 0 | 90.5 | 74 | 75.2 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 85.2 | 80.3 | 75 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 190.3 | 193.1 | 208.7 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 99.7 | 118.5 | 125 | |||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 5.5 | 0 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 13.3 | 20.1 | 13.9 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 13.3 | 25.6 | 13.9 | |||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | -144.1 | -138.8 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 112.9 | 144.1 | 138.8 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 0 | 303.3 | 337.2 | 347.6 | |||||||||||||||||||
balance-sheet.row.account-payables | 0 | 16.1 | 20.7 | 29.5 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 63.3 | 60.8 | 45.1 | |||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 3.1 | 1.5 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 20.3 | 35.2 | 45.2 | |||||||||||||||||||
Deferred Revenue Non Current | 0 | -1.6 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 13.4 | 136.7 | 117.4 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 21.9 | 35.2 | 45.2 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 11.9 | 39.2 | 42.9 | |||||||||||||||||||
balance-sheet.row.total-liab | 0 | 238.7 | 253.5 | 237.2 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 3.7 | 16.8 | 16.8 | |||||||||||||||||||
balance-sheet.row.common-stock | 0 | 189.4 | 189.4 | 189.4 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -401.7 | -379 | -350.9 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -16.8 | -16.8 | -16.8 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 275.3 | 262.2 | 262.2 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 50 | 72.7 | 100.8 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 303.3 | 337.2 | 347.6 | |||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 14.6 | 11 | 9.6 | |||||||||||||||||||
balance-sheet.row.total-equity | 0 | 64.6 | 83.7 | 110.4 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||||
Total Investments | 0 | 0 | 2.7 | 3.3 | |||||||||||||||||||
balance-sheet.row.total-debt | 0 | 83.6 | 96 | 90.3 | |||||||||||||||||||
balance-sheet.row.net-debt | 0 | 77.6 | 89.2 | 63.9 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -26.5 | -44.8 | -50 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 15.4 | 9.5 | 7.1 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -1.7 | -5.3 | 43.5 | ||||||||||||||||||
cash-flows.row.account-receivables | 0 | -2.1 | 0.1 | -4.3 | ||||||||||||||||||
cash-flows.row.inventory | 0 | 1.2 | 16.4 | -2.7 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | 2.1 | -0.1 | 4.3 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -3 | -21.8 | 46.2 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 34 | 35.4 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -8.8 | -33.7 | -14 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -6.4 | 1.1 | 1.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -22.8 | -22 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0.7 | 43.8 | -1.9 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 1.5 | 3 | 10.3 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -12.9 | -8.5 | -26.5 | ||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -46.8 | -16 | -31.2 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 53 | 44.1 | 11 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 6.2 | 28.1 | -20.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -19.6 | 12.9 | -10.7 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 6.9 | 26.4 | 13.5 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 26.4 | 13.5 | 24.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | -12.8 | -6.7 | 36 | ||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -8.8 | -33.7 | -14 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | -21.6 | -40.4 | 22 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 398 | 449.7 | 476.4 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 376.6 | 433.3 | 430.8 | |||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 21.4 | 16.4 | 45.6 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | 0 | -0.3 | -0.1 | -0.5 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 31.2 | 38.5 | 51.8 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 407.8 | 471.8 | 482.5 | |||||||||||||||||||
income-statement-row.row.interest-income | 0 | 0.2 | 0.8 | 0.4 | |||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 5.2 | 6.4 | 5.5 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 7.3 | -5.7 | -40.4 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -0.3 | -0.1 | -0.5 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 7.3 | -5.7 | -40.4 | |||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 5.2 | 6.4 | 5.5 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 11.6 | 15.4 | 9.5 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 0 | -19.3 | -20.8 | -4.4 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -12 | -26.5 | -44.8 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | -1 | 0.2 | -0.1 | |||||||||||||||||||
income-statement-row.row.net-income | 0 | -20.2 | -26.6 | -44.8 |
Dažnai užduodami klausimai
Kas yra Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) bendras turtas?
Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) bendras turtas yra 303277966.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.054.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 0.000.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -0.055.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.045.
Kas yra Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -20159658.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 83557328.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 31200528.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 0.000.